An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review

Abstract

BackgroundThere is a lack of consistency in findings across studies on the prevalence of schizophrenia, and no recent systematic review of the literature exists. The purpose of this study is to provide an updated systematic review of population-based prevalence estimates and to understand the factors that could account for this variation in prevalence estimates.MethodsMEDLINE, Embase, and PsycInfo databases were searched for observational studies describing schizophrenia prevalence in general populations from 2003–2013 and supplemented by studies from a prior review covering 1990–2002. Studies reporting prevalence estimates from specialized populations such as institutionalized, homeless, or incarcerated persons were excluded. Prevalence estimates were compared both across and within studies by factors that might contribute to variability using descriptive statistics.ResultsSixty-five primary studies were included; thirty-one (48 %) were from Europe and 35 (54 %) were conducted in samples of ≥50,000 persons. Among 21 studies reporting 12-month prevalence, the median estimate was 0.33 % with an interquartile range (IQR) of 0.26 %–0.51 %. The median estimate of lifetime prevalence among 29 studies was 0.48 % (IQR: 0.34 %–0.85 %). Prevalence across studies appeared to vary by study design, geographic region, time of assessment, and study quality scores; associations between study sample size and prevalence were not observed. Within studies, age-adjusted estimates were higher than crude estimates by 17 %–138 %, the use of a broader definition of schizophrenia spectrum disorders compared to schizophrenia increased case identification by 18 %–90 %, identification of cases from inpatient-only settings versus any setting decreased prevalence by 60 %, and no consistent trends were noted by differing diagnostic criteria.ConclusionsThis review provides updated information on the epidemiology of schizophrenia in general populations, which is vital information for many stakeholders. Study characteristics appear to play an important role in the variation between estimates. Overall, the evidence is still sparse; for many countries no new studies were identified.Electronic supplementary materialThe online version of this article (doi:10.1186/s12888-015-0578-7) contains supplementary material, which is available to authorized users.

The cost and burden of schizophrenia in Portugal in 2015

“…When applying a 75% adherence rate, the number of prevalent patients was estimated at 48,042, corresponding to a crude prevalence rate in the population >15 years old of 0.57%. This estimate is in line with the results of the systematic review by Simeone et al (2015) [10] (0.52% in the European population in general).…”

“…Estimates were, nonetheless, heterogeneous between studies (variation: 0.21% to 1.3%) [10]. In Portugal, there are no studies on the prevalence of schizophrenia.…”

Development and Feasibility Testing of a Smartphone Intervention to Improve Adherence to Antipsychotic Medications

“…Schizophrenia affects approximately 0.5% of adults worldwide (1) and is among the most severe and costly of psychiatric illnesses (2). When used as prescribed, antipsychotic medications are effective in reducing positive psychotic symptoms, with the aim of improving long-term functional outcomes and enhancing recovery.…”

Association between miR-137 polymorphism and risk of schizophrenia: a meta-analysis

“…The median incidence of this disease is reported to be 15.2 per 100,000 people (McGrath et al, 2008), and its median lifetime prevalence is estimated at 480 per 100,000 patients (Simeone et al, 2015). Moreover, schizophrenia is a major cause of disability (Warner, 2009), with approximately three-quarters of patients suffering an ongoing disability with relapses (Smith et al, 2010).…”